ADPT Adaptive Biotechnologies
- 6.215
- -0.075-1.19%
Adaptive Biotechnologies News
Adaptive Biotechnologies Analyst Ratings
BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $9
Adaptive Biotechnologies Gains Positive Outlook With Strategic Advancements and Increased ClonoSEQ Utilization
Top 3 Health Care Stocks That May Collapse This Quarter
Even After Rising 6.5% This Past Week, Adaptive Biotechnologies (NASDAQ:ADPT) Shareholders Are Still Down 77% Over the Past Five Years
CAR T-cell Therapy Strategic Business Research Report 2024-2030: Allogeneic `Off-the-Shelf` CAR T-Cell Therapies Generate New Opportunities in Manufacturing - ResearchAndMarkets.com
Express News | Adaptive Biotechnologies Announces Over 65 Abstracts Featuring Clonoseq® Mrd Testing Across a Range of Blood Cancers to Be Presented at the 66TH Ash Annual Meeting
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring ClonoSEQ MRD Testing Across a Range of Blood Cancers to Be Presented at the 66th ASH Annual Meeting
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Maintains Target Price $7
Balanced Hold Recommendation for Adaptive Biotechnologies Amid Positive Performance and External Challenges
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Scotiabank Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $10
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 31% Jump Shows Its Popularity With Investors
Adaptive Biotechnologies Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $7
J.P. Morgan Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $7
Express News | Adaptive Biotechnologies Corp : Piper Sandler Raises Target Price to $7 From $6
Q3 2024 Adaptive Biotechnologies Corp Earnings Call
TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating
No Data